Catalyst Brief

← Calendar

Readoutin 14d

Jiangsu HengRui Medicine Co., Ltd. — SHR-A1811

Phase 3 primary completion: A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane.

Date
Dec 2026
Type
Readout
Indication
HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Jiangsu HengRui Medicine Co., Ltd.

  1. Dec2026